Invention Grant
- Patent Title: Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria
- Patent Title (中): 氟酸和抗生素组合用于抑制或治疗多重耐药细菌
-
Application No.: US14383429Application Date: 2013-03-06
-
Publication No.: US09265744B2Publication Date: 2016-02-23
- Inventor: Stephen William Leivers , Peter Warn
- Applicant: Stephen William Leivers , Peter Warn
- Applicant Address: GB Cheshire
- Assignee: NATRACINE UK LIMITED
- Current Assignee: NATRACINE UK LIMITED
- Current Assignee Address: GB Cheshire
- Agency: Cooper & Dunham LLP
- Agent John P. White
- Priority: ZA2012/01683 20120307
- International Application: PCT/IB2013/051772 WO 20130306
- International Announcement: WO2013/132444 WO 20130912
- Main IPC: A01N43/16
- IPC: A01N43/16 ; A01N37/10 ; A61K31/194 ; A61K45/06 ; A61K31/352 ; A61K31/407 ; A61K38/12
Abstract:
Fulvic acid as the active ingredient is used in the treatment or inhibition of multi-drug resistant bacteria, in particular NDM-1 bacteria producing carbapenemase or extended-spectrum β-lactamase (ES8L) resistant bacteria. The multi-drug resistant bacteria may be gram negative bacteria including, but not limited to, Klebsiella pneumoniae or Escherichia coli. The fulvic acid can be provided in combination with one or more antibiotics from the class of carbapenems or polymyxin antibiotics.
Public/Granted literature
- US20150031767A1 FULVIC ACID AND ANTIBIOTIC COMBINATION FOR THE INHIBITION OR TREATMENT OF MULTI-DRUG RESISTANT BACTERIA Public/Granted day:2015-01-29
Information query
IPC分类:
